

Please replace the second full paragraph on page 6 with the following:

A2
The resulting crude peptide was purified by preparative high performance liquid chromatography (HPLC) using a LICHROART® C₁₈ (250. Times. 10) (reverse phase C-18 column)) reverse phase column (Merck, Darmstadt, Germany) on a Preparative HPLC system (Shimadzu Corporation, Japan) using a gradient of 0.1% TFA in acetonitrile and water. The eluted fractions were reanalyzed on Analytical HPLC system (Shimadzu Corporation, Japan) using a C₁₈ LICHROSPHER®, WP-300 (300 X 4) (reverse phase C-18 column) reverse-phase column. Acetonitrile was evaporated and the fractions were lyophilized to obtain the pure peptide. The identity of each peptide was confirmed by electron-spray mass spectroscopy.

In the Claims

Please cancel claims 10-13.

Please amend the following claims.

A3
Claim 1. (amended) A peptide derivative of the formula
X-Leu-Met-Tyr-Pro-Thr-Tyr-Leu-Lys-Y (SEQ ID NO:7)
wherein, X is acetyl or straight, branched, or cyclic alkanoyl group from 3-16 carbon atoms and

Y is carboxy terminal residue selected from OH or amino; or a pharmaceutical acceptable salt of the peptide.

Claim 2. (amended) A peptide derivative of claim 1, wherein the alkanoyl group is selected from the group consisting of acetyl, n-butanoyl, n-hexanoyl, n-octanoyl, lauroyl, myristoyl, palmitoyl, isohexanoyl, cyclohexanoyl, cyclopentylcarbonyl, n-heptanoyl, n-decanoyl, n-undecanoyl, and 3,7-dimethyloctanoyl.

A4
Claim 7. (amended) A peptide derivative of claim 1, wherein X is Palmitoyl and the peptide is:

Palmitoyl-Leu-Met-Tyr-Pro-Thr-Tyr-Leu-Lys-OH (SEQ ID NO:6)
or a pharmaceutically acceptable salt thereof.

Claim 8. (amended) A composition comprising a polypeptide according to claim 1, and a pharmaceutically acceptable carrier.

Claim 9. (amended) A method of treatment of cancer in mammals which comprises the administration of a polypeptide according to claim 1, alone or in combination with other polypeptides or anticancer compounds in an amount effective to treat with cancer.

05
Claim 14. A composition comprising the peptide of claim 2 and a pharmaceutically acceptable carrier.

Claim 15. A composition comprising the peptide of claim 3 and a pharmaceutically acceptable carrier.

Claim 16. A composition comprising the peptide of claim 4 and a pharmaceutically acceptable carrier.

Claim 17. A composition comprising the peptide of claim 5 and a pharmaceutically acceptable carrier.

Claim 18. A composition comprising the peptide of claim 6 and a pharmaceutically acceptable carrier.

Claim 19. A composition comprising the peptide of claim 7 and a pharmaceutically acceptable carrier.

Claim 20. A method for treating a cancer selected from the group consisting of colon, oral, glioblastoma, breast, laryngeal, endothelial, ovarian and lung comprising administering to a patient in need thereof a peptide according to claim 1 in an amount effective to treat the cancer.

Claim 21. A method for treating a cancer selected from the group consisting of colon, oral, glioblastoma, breast, laryngeal, endothelial, ovarian and lung comprising administering to a patient in need thereof a peptide according to claim 2 in an amount effective to treat the cancer.

Claim 22. A method for treating a cancer selected from the group consisting of colon, oral, glioblastoma, breast, laryngeal, endothelial, ovarian and lung comprising administering to a patient in need thereof a peptide according to claim 3 in an amount effective to treat the cancer.

Claim 23. A method for treating a cancer selected from the group consisting of colon, oral, glioblastoma, breast, laryngeal, endothelial, ovarian and lung comprising administering to a patient in need thereof a peptide according to claim 4 in an amount effective to treat the cancer.

Claim 24. A method for treating a cancer selected from the group consisting of colon, oral, glioblastoma, breast, laryngeal, endothelial, ovarian and lung comprising administering to a patient in need thereof a peptide according to claim 5 in an amount effective to treat the cancer.

Claim 25. A method for treating a cancer selected from the group

AS
Conclude

consisting of colon, oral, glioblastoma, breast, laryngeal, endothelial, ovarian and lung comprising administering to a patient in need thereof a peptide according to claim 6 in an amount effective to treat the cancer.

Claim 26. A method for treating a cancer selected from the group consisting of colon, oral, glioblastoma, breast, laryngeal, endothelial, ovarian and lung comprising administering to a patient in need thereof a peptide according to claim 7 in an amount effective to treat the cancer.

Claim 27. The method according to any one of claims 20 to 26 further comprising administering a second polypeptide or anticancer compound.
